Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s stock price was down 2% during trading on Friday . The company traded as low as C$0.97 and last traded at C$0.98. Approximately 9,578 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 64,439 shares. The stock had previously closed at C$1.00.
Medicenna Therapeutics Stock Performance
The company has a market capitalization of C$74.82 million, a price-to-earnings ratio of -2.75 and a beta of 1.21. The company has a debt-to-equity ratio of 0.88, a current ratio of 11.40 and a quick ratio of 4.65. The company's 50-day moving average price is C$1.15 and its two-hundred day moving average price is C$1.63.
Insider Transactions at Medicenna Therapeutics
In related news, Senior Officer David Hyman acquired 20,000 shares of the company's stock in a transaction dated Thursday, January 9th. The shares were purchased at an average price of C$1.45 per share, for a total transaction of C$29,000.00. Corporate insiders own 22.57% of the company's stock.
About Medicenna Therapeutics
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Featured Articles
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
